## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nicholas Pullen, et al.

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: COMBINATIONS OF ATORVASTATIN AND : a1 ADRENERGIC RECEPTOR ANTAGONISTS

Hon. Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: Other Composit 16, 2003

Carl J. Goddard

Attorney for Applicant(s)

Reg. No. 39,203

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (860) 441-4902

INFORMATION DISCLOSURE CITATION								ATTY. DOCKET NO. PC25214A					SERIAL NO. To be assigned				
(Use several sheets if necessary)								APPLICANT Nicholas Pullen, et al.							_		
								FILING DATE Concurrently herewith					GROUP To be assigned				
		_					U.:	S. PATEN	T DOC	UMENTS							
EXAMINER INITIAL			DOCUMENT NUMBER								NAME		CLASS	SUBCLASS	FILING IF APPRO	DATE OPRIATE	
	us		5	2	7	3	9	9	5	12/28/93	Roth		514	422			
								1			<u></u>						
		+	_					<del>                                     </del>									
				•													
	ļ	╀															
		$\perp$				·											
,																	
	1					F	ORE	EIGN PAT	ENT DO	CUMENT	rs						
													CLASS				
DOCUMENT NUMBER										DATE	COUNTRY	COUNTRY		SUBCLASS			
		Τ													YES	NO	
	ļ	-															
	<del> </del>	ļ.,															
		<u> </u>															
		-				<u> </u>											
								_									
				ОТН	ER DO	CUMENTS	S (In	ncluding A	uthor, T	itle, Date,	Pertinent Pa	ges, l	≣tc.)				
			Furuya, S. et al., The Journal of Urology, Vol. 128, pp. 836-839, October, Alpha-Adrenergic Activity and Urethral Pressure in Prostatic Zone in Benign Prostatic Hypertrophy."														
		T	Hieble, J. P. et al., Pharmacological Research, Vol. 33, No. 3, 1996, "The Use of α-Adrenoceptor Antagonists in the														
	$\perp$	$\downarrow$	Pharm	, J. P. et acologica	ai., Pham al Manage	ement of Be	rese nign	earch, Vol. 33 Prostatic Hy	s, No. 3, 1 pertrophy	996, "The U An Overvie	se of α-Adrenoc w."	eptor A	ntagonists	s in the			
EXAMINE	R								DATE C	ONSIDERE	 D						
								·		· · ·							
EXAMINER: next commun	Initial if lication t	refere o appi	nce cons licant.	idered, whe	ther or not ci	tation is in confo	ormano	ce with MPEP 60	9; Draw line	through citation	if not in conformance	and not c	onsidered. In	dude copy of this	s form wi	th	

Conforms with FORM PTO-FB-A820 INFORMATION DISCLOSURE